A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-03-17

Summary

This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.

Study details include:

• The study duration will be up to 12 months per participant.
• The treatment duration will be up to 24 weeks.
• The number of visits will be 7.

• Phase: PHASE4

Details

• Lead Sponsor: Sanofi
• Treatments: belumosudil